Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
about
Uricosuric medications for chronic goutAllopurinol for chronic gout2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaEULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?Gout: optimizing treatment to achieve a disease cureThe effect of angiotensin II receptor blockers on hyperuricemiaImpact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsAssociations of non-high density lipoprotein cholesterol and traditional blood lipid profiles with hyperuricemia among middle-aged and elderly Chinese people: a community-based cross-sectional studyEffects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.An old disease with new insights: Update on diagnosis and treatment of gout.Emerging therapies in the long-term management of hyperuricaemia and gout.New and improved strategies for the treatment of goutDiagnosis and management of gout: a rational approachEffect of Urate-Lowering Therapy on All-Cause and Cardiovascular Mortality in Hyperuricemic Patients without Gout: A Case-Matched Cohort StudyFebuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.An update on the treatment options for gout and calcium pyrophosphate deposition.Gout. Novel therapies for treatment of gout and hyperuricemia.Gout--what are the treatment options?The challenges of gout management in the elderly.Gout and organ transplantation.Gout and its comorbidities: implications for therapy.Chronic gout in the elderly.Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes.Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review.Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).Gout: An old disease in new perspective - A review.Effect of fenofibrate in combination with urate lowering agents in patients with gout.Fenofibrate and losartan.The relationship of apolipoprotein B and very low density lipoprotein triglyceride with hyperuricemia and goutThe British Society for Rheumatology Guideline for the Management of Gout.
P2860
Q24187988-DF18C226-3A7B-406D-ABF7-A26D8EF237B7Q24193107-20A346F5-730E-4B49-A4DB-BE9706B14097Q24612292-0EDA81D6-0250-454D-9A23-7C8FEC096435Q24675150-5C492219-ADEB-462F-B463-D8AEBC54CA7CQ24678615-5CFC622B-CB5C-47C8-BCAD-D4F49FA6A570Q26765550-47460611-96A3-4527-953C-ECE8459F8D9AQ26777082-2755F665-EFD7-4294-924D-469A3CCE4576Q33864537-E4B08050-9F1F-4436-A7E1-1A273113136BQ33971640-61CF0A96-2D10-4C56-ABA0-0EDE91D11630Q34466646-E2DEF3FE-6D44-4AD8-9754-0B7B8E04C28AQ34542091-573A1DC6-5D75-4F5E-97FE-C7FBC1A7F78CQ34578135-A37263FA-F54D-4155-B9BC-0EFF6FE725D1Q35026692-65C68CF9-B3F0-497C-920A-7AD216C58511Q35522716-4C084367-6E7A-4B93-8DB7-FF3E6A591DF4Q35873062-20CE07B3-212B-4AC1-A736-0CABF02B718BQ36196489-86B887B8-F685-491E-B106-E3459381A882Q36301585-0452291C-041D-4183-9CB5-44836AB86000Q37350841-9912D3CA-37F0-42D0-AC92-EAB720A080FBQ37492596-4C8AD06F-5027-4324-B8E2-8D9EAD69B7A2Q37910891-2514F8D4-33DC-4571-88EC-5DF49E7FCE23Q37976996-357C99A6-DAC4-4FEC-A257-29CFCDA4D814Q38040777-AB7D20B6-2D1E-4B22-BD88-644FDE9A5DB1Q38112326-3ADA8DE1-0691-4438-A46C-91B14DC06BE7Q38160494-3FC8E5DF-813E-47AD-BE25-101B1F7F83BBQ38268302-3CAB88FF-4583-4EB1-B805-185560759021Q38853112-217D81ED-281F-484F-BA92-15E35BCC714BQ39207518-EEFF21B3-B336-4E07-A287-EF96B4974309Q40106739-0BD1D9D4-0B4B-4BA6-93F9-E88D023F9DE4Q41869801-71519A7B-B01D-48A7-88B6-1B9093D7FAE3Q41904610-4A268DED-1D3C-4A6F-9DD0-095A41DCB02CQ42135402-53186056-275B-4CE5-8222-EF0296EA1B74Q55060116-EEC9EC23-0600-4F3B-8615-2E7DE22185D8
P2860
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Effects of combination treatme ...... artan on uric acid metabolism.
@en
type
label
Effects of combination treatme ...... artan on uric acid metabolism.
@en
prefLabel
Effects of combination treatme ...... artan on uric acid metabolism.
@en
P2093
P356
P1476
Effects of combination treatme ...... artan on uric acid metabolism.
@en
P2093
P304
P356
10.1136/ARD.62.6.572
P407
P577
2003-06-01T00:00:00Z